NASDAQ · JANX
Healthcare · Biotechnology
$17.46
Down-$0.01 (-0.06%)
Updated Nov 3, 2026, 12:51 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · JANX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
JANX closed at $17.46 after 21 trading sessions, up 5.56% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $17.50 | $17.82 | $17.40 | $17.46 | 412.94K |
| Oct 30, 2026 | $17.925 | $18.17 | $17.13 | $17.47 | 540.04K |
| Oct 29, 2026 | $18.18 | $18.62 | $17.70 | $17.83 | 905.87K |
| Oct 28, 2026 | $17.01 | $18.07 | $16.89 | $18.05 | 984.2K |
| Oct 27, 2026 | $16.68 | $17.63 | $16.4242 | $17.26 | 687.23K |
| Oct 26, 2026 | $16.80 | $17.18 | $16.51 | $16.69 | 379.23K |
| Oct 23, 2026 | $16.94 | $16.94 | $16.27 | $16.66 | 378.88K |
| Oct 22, 2026 | $16.88 | $17.26 | $16.575 | $17.06 | 514.25K |
| Oct 21, 2026 | $17.22 | $17.465 | $16.79 | $16.93 | 587.43K |
| Oct 20, 2026 | $16.80 | $17.66 | $16.715 | $17.20 | 869.45K |
| Oct 19, 2026 | $16.61 | $16.87 | $16.46 | $16.74 | 915.06K |
| Oct 16, 2026 | $17.27 | $17.27 | $16.43 | $16.51 | 765.88K |
| Oct 15, 2026 | $17.30 | $17.62 | $17.02 | $17.32 | 546.9K |
| Oct 14, 2026 | $17.13 | $17.49 | $16.84 | $17.13 | 614.67K |
| Oct 13, 2026 | $18.06 | $18.135 | $16.97 | $17.18 | 795.92K |
| Oct 12, 2026 | $18.29 | $18.605 | $17.96 | $18.15 | 802.99K |
| Oct 9, 2026 | $18.42 | $19.18 | $18.32 | $18.39 | 1.17M |
| Oct 8, 2026 | $17.77 | $18.90 | $17.30 | $18.50 | 1.5M |
| Oct 7, 2026 | $16.52 | $18.365 | $16.42 | $17.92 | 1.21M |
| Oct 6, 2026 | $16.69 | $17.37 | $16.31 | $16.79 | 809.85K |
| Oct 5, 2026 | $16.93 | $16.95 | $16.13 | $16.54 | 533.74K |
The latest Smart Investors Daily articles mentioning JANX.
Company
Market Activity
Research & News
JANX research
Company profile and research snapshot.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Wolfe Research | Outperform | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
| May 8, 2026 | Piper Sandler | Overweight | — |
| May 8, 2026 | Guggenheim | Buy | — |
| May 8, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Feb 27, 2026
Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $150 to $100.
Benzinga · Feb 27, 2026
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $72 to $68.
Benzinga · Feb 26, 2026
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.64) by 20.19 percent. This is a 41.67 percent decrease over losses of $(0.36) per share
SeekingAlpha · Dec 9, 2025
2025-12-09. The following slide deck was published by Janux Therapeutics, Inc.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning JANX.
